National Institutes for Food and Drug Control;
Beijing 102629;
China;
State Key Laboratory of Natural Medicines;
Ministry of Education;
the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province;
Department of Marine Pharmacy;
China;
Pharmaceutical University;
Nanjing 211198;
ChinaAffiliated Hospital of Chifeng College;
Inner Mongolia Autonomous Region 024005;
China;
Integrins; Extracellular matrix; Tumor progression; Targeted drug; Antagonists; Clinical trial;